Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neuroblastoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Limbic Encephalitis 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Epilepsy 1Epilepsies, Partial 1Drug Resistant Epilepsy 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

Dexamethasone 17Melphalan 14Bortezomib 10Calcium Dobesilate 8Filgrastim 6Granulocyte Colony-Stimulating Factor 5Cyclophosphamide 5birtamimab 4dexamethasone acetate 3Whole-Body Irradiation 3Thalidomide 3Peripheral Blood Stem Cell Transplantation 3Lenalidomide 3fludarabine phosphate 2daratumumab 2Mycophenolic Acid 2Etoposide 2Doxycycline 2Darbepoetin alfa 2Cyclosporine 2Busulfan 2Blood Component Removal 2pomalidomide 1pegfilgrastim 1ixazomib 1isatuximab 1ferrous sulfate 1ferric gluconate 1dexamethasone 21-phosphate 1carfilzomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Immunoglobulin Light-chain Amyloidosis × Immunoglobulins, Intravenous × Clear all
NCT00547365 2013-09-19

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction

University of Tennessee

Phase 1/2 Completed
10 enrolled 4 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡